Young Kim

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis (NASH).

I. Sancho-Martinez, P. McNamara, S. Joseph, 2020, Journal of medicinal chemistry.

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).

P. McNamara, S. Joseph, B. Laffitte, 2017, Journal of medicinal chemistry.

Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.

P. McNamara, S. Joseph, R. Epple, 2014, Bioorganic & medicinal chemistry letters.

Relative Potency Estimation of Dioxin-like Activity by Dioxins , Furans , and Coplanar PCBs Using Chemically Activated Luciferase Gene Expression Assay ( H 4 IIE-luc Assay )

J. Giesy, K. Lee, J. Khim, 2010 .

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2

Sungjoon Kim, Nanxin Li, M. Warmuth, 2013, Journal of medicinal chemistry.

Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents

P. McNamara, W. Dietrich, J. Walker, 2019, Hepatology communications.